Discontinuation of Guanfacine in an 18-Year-Old with ADHD
Yes, guanfacine should be discontinued since it is no longer effective after one year of use, but it must be tapered gradually over 1-2 weeks rather than stopped abruptly to prevent rebound hypertension. 1, 2
Why Discontinue
Since guanfacine has lost effectiveness after a year of treatment and atomoxetine has been started for better ADHD management, continuing an ineffective medication exposes the patient to unnecessary side effects (somnolence, bradycardia, hypotension) without therapeutic benefit 1. The evidence shows that somnolence is a major reason for early guanfacine discontinuation, and lack of efficacy is a clear indication to switch medications 3.
Critical Safety Concern: Tapering is Mandatory
The most important clinical consideration is that guanfacine and clonidine must never be stopped abruptly. The 2019 AAP/AACAP guidelines explicitly state: "Because rebound hypertension after abrupt guanfacine and clonidine discontinuation has been observed, these medications should be tapered off rather than suddenly discontinued" 1. The FDA label reinforces this, warning that "abrupt cessation of therapy with orally active central α2-adrenergic agonists may be associated with increases in plasma and urinary catecholamines, symptoms of nervousness and anxiety, and less commonly, increases in blood pressure to levels significantly greater than those prior to therapy" 2.
Recommended Tapering Schedule
Based on the evidence, here is the specific approach:
For an 18-year-old on guanfacine:
- Week 1: Reduce dose by 25-50% (e.g., if on 4mg, reduce to 2mg)
- Week 2: Reduce to 1mg
- Days 11-14: Continue 1mg then discontinue
A study in young adults (ages 19-24) demonstrated that even abrupt cessation at 4mg did not cause clinically significant rebound hypertension 4, but given FDA warnings and guideline recommendations, tapering remains the standard of care to minimize any risk.
Monitoring During Taper
Monitor the following parameters every 3-4 days during the taper:
- Blood pressure and heart rate (watch for rebound hypertension - SBP/DBP increases above baseline)
- Symptoms of withdrawal: nervousness, anxiety, agitation
- ADHD symptom control (may worsen during taper before atomoxetine reaches full effect)
Timing with Atomoxetine
You can taper guanfacine while atomoxetine is being titrated. Atomoxetine takes 4-6 weeks to reach full therapeutic effect 5, so there will be a period of suboptimal ADHD control. The guidelines note that atomoxetine and guanfacine have been used together off-label 1, so brief overlap during the taper is safe and may provide better symptom coverage during the transition.
Key Cardiovascular Considerations
Be aware of opposing cardiovascular effects:
- Guanfacine decreases heart rate and blood pressure (mean decreases of ~2-4 mm Hg SBP/DBP and 4-6 bpm pulse) 6
- Atomoxetine increases heart rate and blood pressure (mean increases of ~2 mm Hg and variable pulse changes) 1
As guanfacine is tapered, the patient's baseline BP and HR will likely rise back toward pre-treatment levels, then may increase further with atomoxetine. This is generally not clinically significant in healthy young adults, but monitor vital signs.
Common Pitfall to Avoid
Do not abruptly stop guanfacine even though the patient is young and healthy. While one study showed minimal rebound in healthy young adults 4, this patient has been on guanfacine for a full year, and the FDA black box warning about rebound hypertension with alpha-2 agonists applies regardless of age or health status 2. The risk-benefit clearly favors a 1-2 week taper.
What to Tell the Patient
Explain that:
- Guanfacine will be gradually reduced over 1-2 weeks to prevent blood pressure spikes
- ADHD symptoms may temporarily worsen during the transition before atomoxetine reaches full effect (4-6 weeks)
- Report immediately: severe headache, chest pain, rapid heartbeat, severe anxiety, or blood pressure readings consistently >140/90
- Continue atomoxetine as prescribed even if symptoms initially worsen